Improving treatment strategies for patients with metastatic castrate resistant prostate cancer through personalized computational modeling

[1]  Yang Kuang,et al.  Mechanisms of resistance to intermittent androgen deprivation in patients with prostate cancer identified by a novel computational method. , 2014, Cancer research.

[2]  R. DiPaola,et al.  Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David Basanta,et al.  An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. , 2014, Cancer research.

[4]  Jeremy Gunawardena,et al.  Models in biology: ‘accurate descriptions of our pathetic thinking’ , 2014, BMC Biology.

[5]  B. Ross,et al.  Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules , 2014, Cell.

[6]  Douglas A Lauffenburger,et al.  Addressing genetic tumor heterogeneity through computationally predictive combination therapy. , 2013, Cancer discovery.

[7]  K. Pienta,et al.  Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets , 2013, Proceedings of the National Academy of Sciences.

[8]  Raffaella Casadei,et al.  An estimation of the number of cells in the human body , 2013, Annals of human biology.

[9]  Dominic Trewartha,et al.  Advances in prostate cancer treatment , 2013, Nature Reviews Drug Discovery.

[10]  N. Maitland,et al.  JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. , 2013, Cancer research.

[11]  J. Melo,et al.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. , 2013, Blood.

[12]  P. Kantoff,et al.  New developments in the management of prostate cancer. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  O. Sartor,et al.  Enzalutamide for the treatment of prostate cancer , 2013, Expert opinion on pharmacotherapy.

[14]  R. Cardiff,et al.  Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. , 2012, Cancer research.

[15]  Kenneth Chang,et al.  Modulators of Prostate Cancer Cell Proliferation and Viability Identified by Short-Hairpin RNA Library Screening , 2012, PloS one.

[16]  Janet E Brown,et al.  Denosumab in patients with cancer—a surgical strike against the osteoclast , 2012, Nature Reviews Clinical Oncology.

[17]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[18]  Zhibin Huang,et al.  A Generalized Linear-Quadratic Model for Radiosurgery, Stereotactic Body Radiation Therapy, and High–Dose Rate Brachytherapy , 2010, Science Translational Medicine.

[19]  Naoto T. Ueno,et al.  Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST , 2010, Journal of Cancer.

[20]  K Hendrickson,et al.  Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach , 2010, Physics in medicine and biology.

[21]  Chronic Disease Division.  Cancer facts and figures , 2010 .

[22]  P. Rotwein,et al.  Akt promotes BMP2-mediated osteoblast differentiation and bone development , 2009, Journal of Cell Science.

[23]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  B. Leiby,et al.  Transcription Factor Signal Transducer and Activator of Transcription 5 Promotes Growth of Human Prostate Cancer Cells In vivo , 2008, Clinical Cancer Research.

[25]  R. Agarwal,et al.  Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. , 2007, Carcinogenesis.

[26]  J. Bartlett,et al.  Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer , 2007, British Journal of Cancer.

[27]  J. McCall,et al.  Genetic algorithms for modelling and optimisation , 2005 .

[28]  Liang Cheng,et al.  Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. , 2004, Anticancer research.

[29]  S. Steinberg,et al.  Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  I Judson,et al.  Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.

[31]  E. Jones,et al.  Osteoblast-Derived Factors Induce Androgen-Independent Proliferation and Expression of Prostate-Specific Antigen in Human Prostate Cancer Cells , 2004, Clinical Cancer Research.

[32]  Kevin Regan,et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Zijie Sun,et al.  Phosphatidylinositol 3-Kinase/Akt Stimulates Androgen Pathway through GSK3β Inhibition and Nuclear β-Catenin Accumulation* , 2002, The Journal of Biological Chemistry.

[34]  G. Mundy.  Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.

[35]  M. Baslé,et al.  Activation of the Jak/Stat signal transduction pathway in GH-treated rat osteoblast-like cells in culture , 2000, Molecular and Cellular Endocrinology.

[36]  Peter J. Bentley,et al.  Aspects of Evolutionary Design by Computers , 1998, ArXiv.

[37]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  T. Nishiyama.  Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature. , 2014, Urologic oncology.

[39]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[40]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[41]  Zijie Sun,et al.  Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. , 2002, The Journal of biological chemistry.

[42]  Peter J. Bentley,et al.  Evolutionary Design By Computers , 1999 .